• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

byJessie WillisandTeddy Guo
December 2, 2021
in Chronic Disease, Hematology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%.

2. No dose-limiting toxic effects were observed, and no patients discontinued treatment due to toxic effects.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nearly half of patients treated for non-Hodgkin lymphoma become treatment refractory or relapse after treatment. Epcoritamab, a bispecific CD3 and CD20 antibody, is a potential subcutaneous therapy that has shown promise in other hematological malignancies. In this phase I/II drug study, 68 patients with relapsed or refractory B-cell non-Hodgkin lymphoma received escalating doses of epcoritamab. The primary outcome was to determine a maximum tolerated dose and a recommended phase II does for epcoritamab. Epcoritamab was relatively well-tolerated, as no dose-limiting toxic effects were observed, and no discontinuation was seen due to toxic effects. The most common adverse event was fever, usually associated with cytokine release syndrome (CRS). All cases of CRS were grade 1-2 and did not require ICU admission. More than half of patients discontinued treatment due to disease progression. During treatment, 16% of patients died due to disease progression and this would increase to 56% during follow-up. However, treatment response was reported in many patients, varying from partial response of 68%-100% depending on dosages and cancer subtype. In the end, 48 mg of subcutaneous epcoritamab was determined to be the recommended dose for continued evaluation in clinical trials with no maximum tolerated dose reached in this trial.

Click to read the study in the Lancet

Relevant Reading: Outcomes in refractory diffuse large Bcell lymphoma: results from the international SCHOLAR­1 study.

In-Depth [randomized controlled trial]: This phase 1/2 drug study was started across Denmark, the Netherlands, the UK, and Spain in 2018. Eligibility criteria for this study included patients aged 18+ with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin lymphoma. All subtypes of B-cell non-Hodgkin lymphoma were included. All patients were to be previously treated with the standard treatment of a CD20 monoclonal antibody regimen. The dose-escalation (phase 1) regimen for this study was defined as a priming dose on day 1, an intermediate dose (1.5 mg) on day 8, followed by 28-day cycles of full-dosages (0.0128 mg – 60 mg). Cycles 1 and 2 were weekly injections, 2-6 were every two weeks, and 7+ were every 4 weeks. Injections were given with corticosteroids, antipyretics, and antihistamines. Dose escalation was determined by observation of dose-limiting toxic effects. Treatment response was evaluated every 6 weeks for the first 24 weeks, followed by every 24 weeks after. Radiographic disease was measured by FDG-PET-CT scans.

RELATED REPORTS

Efanesoctocog alfa is efficacious in treating severe hemophilia A

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Early-life body size not an independent risk factor for colorectal cancer

68 patients (34% female) partook in this study with an average age of 68 years (IQR 57-75). 68% of patients discontinued treatment due to disease progression with only 22% of patients remaining on the treatment until the end of the study period. 16% of patients died during the treatment period, all due to disease progression, and this increased to 56% of patients during post-treatment follow-up. Serious adverse events occurred in 68% of patients, with 28% of total patients experiencing serious pyrexia. There were no discontinuations due to treatment-related adverse events.

In those with diffuse large B-cell lymphoma, 68% (95% CI 45-86%) responded to treatment (45% complete response). There was a dose-related effect seen. The response rate was 88% (47-100) at 48 mg and 100% (29-100) at 60 mg. For those with follicular lymphoma, response rate was 90% (50% complete response) at 0.76-48 mg.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aggressive b-cell lymphomab cell non hodgkin lymphomaB-cell lymphomaB-cell malignancyDiffuse large B-cell lymphoma (DLBCL)follicular lymphomahematologymantle cell lymphomaNon-Hodgkin Lymphomaoncologyrelapsed and refractory lymphomarelapsed refractory b cell lymphoma
Previous Post

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

Next Post

Peripherally inserted central catheters are associated with twice as many complications than midline catheters when used short-term

RelatedReports

Nonleg venous thromboses associated with PE, longer ICU stay
Chronic Disease

Efanesoctocog alfa is efficacious in treating severe hemophilia A

February 2, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Early-life body size not an independent risk factor for colorectal cancer

January 11, 2023
Similar outcomes after supracervical vs. total hysterectomy
Oncology

Characterization of prognostic markers of residual neoplastic disease following hysterectomy

January 4, 2023
Next Post
Surgical site anesthetic infusion may enhance analgesia after mastectomy

Peripherally inserted central catheters are associated with twice as many complications than midline catheters when used short-term

AAP recommends focus on nutrient-rich foods in schools

Smartphone-based intervention reduced body mass index and obesity in school children

Genetic, environmental risk assessment does not increase colon cancer screening

Capecitabine + oxaliplatin chemoradiotherapy does not increase survival, but increases toxicity, compared to capecitabine alone in the postoperative treatment of rectal cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options